TG Therapeutics, Inc.

NASDAQ:TGTX

25.71 (USD) • At close October 29, 2024
Bedrijfsnaam TG Therapeutics, Inc.
Symbool TGTX
Munteenheid USD
Prijs 25.71
Beurswaarde 3,980,499,330
Dividendpercentage 0%
52-weken bereik 7.17 - 26.41
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael S. Weiss Esq.
Website https://www.tgtherapeutics.com

An error occurred while fetching data.

Over TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of

Vergelijkbare Aandelen

DocGo Inc. logo

DocGo Inc.

DCGO

3.48 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

17.26 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

21.77 USD

Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp.

AVXL

5.715 USD

Alector, Inc. logo

Alector, Inc.

ALEC

5.07 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

8.65 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

3.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)